Introduction
============

Most catalase-positive, gram-positive rods, commonly called coryneform or diphtheroid bacteria, have historically been considered simple contaminants that are unlikely to be pathogenic, when isolated from clinical specimens. Of the \>80 species of *Corynebacterium* that have been reported, \~50 species rarely cause infectious diseases in humans.[@b1-idr-12-161] *Corynebacterium striatum* is one of the more commonly isolated coryneform bacteria in clinical microbiology laboratories.

In the last decade, *C. striatum* has been frequently cultured from various surfaces and medical equipment in hospital settings.[@b2-idr-12-161] In clinical settings, *C. striatum* is increasingly being recognized as a source of opportunistic diseases in immunocompromised patients suffering from malignancies, human immunodeficiency virus infection, or chronic lung diseases, and in patients wearing prosthetic devices. Furthermore, *C. striatum* is potentially pathogenic in patients with chronic diseases, who are exposed to specific circumstances, such as invasive medical procedures, prolonged use of broad-spectrum antibiotics, or long-term hospitalization.[@b3-idr-12-161]--[@b5-idr-12-161]

Occasionally, *C. striatum* strains are isolated in polymicrobial infections, where their degree of virulence remains largely undetermined. In reality, it is difficult to distinguish between a pathogen causing infection and one causing colonization. Although the clinical significance and prevalence of *C. striatum* remain unclear, this organism has been responsible for a variety of infections, such as bacteremia, arthritis, osteomyelitis, meningitis, endocarditis, breast abscess, peritonitis, wound infections, and prosthetic joint infections in both immunocompetent and immunocompromised patients.[@b3-idr-12-161]--[@b6-idr-12-161]

Infections caused by *C. striatum* are usually considered to originate endogenously. However, recent studies have documented the possibility of patient-to-patient transmission of *C. striatum*. The bacterium may cause serious nosocomial infections in intensive care unit patients and spread from patient to patient via physical contact with attending personnel or via the nosocomial environment itself.[@b7-idr-12-161]--[@b9-idr-12-161]

Despite early reports of susceptibility to a wide range of antibiotics, multidrug-resistant phenotypes have been recently reported in most *C. striatum* strains.[@b2-idr-12-161],[@b10-idr-12-161] Moreover, multidrug-resistant *C. striatum* may cause nosocomial transmissions resulting in outbreaks in patients with specific risk factors, leading to increased mortality.[@b2-idr-12-161],[@b11-idr-12-161]

There is limited information on the pathogenicity and clinical implications associated with *C. striatum* strains in a clinical setting. The aim of this study was to investigate the molecular characteristics, clinical significance, and antimicrobial susceptibility of *C. striatum*, with the goal of increased understanding of its pathogenicity.

Patients and methods
====================

Study design
------------

An observational study was conducted at the Korea University Anam Hospital, a 1,048-bed university hospital in Seoul, Republic of Korea (ROK) from August 2016 to December 2016. All subjects were adult patients (\>18 years) whose clinical isolates obtained from diagnostic cultures of clinical specimens tested positive for *C. striatum*. If multiple *C. striatum* isolates were recovered from a patient, only the first isolate was included in the study.

This study was performed in compliance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Korea University Anam Hospital (No. 2018AN0161). As this observational study did not entail any deviations from routine medical practice, the requirement for informed consent was waived.

Clinical data
-------------

Clinical data manually extracted from medical records included age, gender, comorbidities, clinical diagnoses, specimen categories, Charlson's comorbidity index, microbiological data, and treatment outcomes. Determination of the clinical significance of *C. striatum* isolates was based on clinical findings, such as fever, white blood cell counts, and C-reactive protein, in addition to whether the patient had or had not received antibiotics for *C. striatum*. Infections were categorized as community acquired, health care associated, or nosocomial, depending on the location that the stains were isolated from. Treatment outcomes were classified on the basis of in-hospital mortality and median length of hospitalization since *C. striatum* isolation. Additionally, demographic, clinical, and microbiological characteristics between the antibiotic treatment group and the observation group were compared.

*C. striatum* identification
----------------------------

Processing and incubation of all clinical samples was performed according to routine laboratory protocols. *C. striatum* isolates were initially identified using the MicroScan WalkAway-96 Plus system (Beckman Coulter, Inc., Brea, CA, USA) and further confirmed by sequencing of the entire 16S rRNA gene.

The *C. striatum* strains were cultured on blood agar plates for 18 hours at 37°C. The cultured colony was suspended in 200 µL of lysis buffer, incubated overnight at 37°C, and centrifuged for 5 minutes at 3,000 rpm. The pelleted bacteria were suspended in 500 µL of sterile water and boiled for 15 minutes for DNA extraction. *C. striatum* DNA was extracted using a bacterial AccuPrep Genomic DNA Extraction Kit (Bioneer, Daejeon, ROK). To amplify 16S rRNA, universal primers 16SF27 (5′-AGAGTTTGATCMTGGCTCAG) and 16SR1492 (5′-TACGGYTACCTTGTTACGACTT) were used, as previously described.[@b12-idr-12-161] The purified PCR product was sequenced using primer walking with the oligonucleotides using the primers 16SF518 (5′-CCAGCAGCCGCGGTA-ATAC) and 16SR800 (5′-TACCAGGGTATCTAATCC).[@b13-idr-12-161]

The amplified sequence was compared with those available in the GenBank database using the BLAST program. 16S rRNA sequences were aligned with Clustal W multisequence alignment program. Phylogenetic trees were constructed using the neighbor-joining genetic distance method and the MEGA 7.0 program package. The Kimura two-parameter model was chosen for all neighbor-joining tree constructions. Reliability of each tree topology was checked with 1,000 bootstrap replications.[@b14-idr-12-161] Phylogenetic analysis confirmed that all 16S rRNA gene sequences of the 67 isolates were 98%--99% homologous to *C. striatum* ATCC 6940 isolates ([Figure 1](#f1-idr-12-161){ref-type="fig"}).

Antimicrobial susceptibility
----------------------------

Susceptibility to antibiotics was tested using *Streptococcus* MicroScan panel (Beckman Coulter, Inc.) and the MicroScan WalkAway-96 Plus system (Beckman Coulter, Inc.), which are considered the gold standard culture media for *Corynebacterium* as recommended by the Clinical and Laboratory Standards Institute (CLSI). The minimum inhibitory concentration (MIC) breakpoint for *Corynebacterium* (CLSI document M45-A2) was applied for the analysis of antimicrobial susceptibility.[@b15-idr-12-161]

Multilocus sequence typing (MLST)
---------------------------------

For MLST, the internally transcribed spacer 1 (ITS1) region, as well as *gyrA* and *rpoB* were amplified and sequenced for *C. striatum* strains.[@b2-idr-12-161] The primers used are provided in [Table S1](#SD1-idr-12-161){ref-type="supplementary-material"}. PCR amplification and sequence reaction were performed as previously described.[@b16-idr-12-161]--[@b18-idr-12-161]

Statistical analyses
--------------------

Categorical variables are expressed as frequencies and were analyzed using Pearson's chi-squared test or Fisher's exact test. Continuous variables are expressed as medians and IQRs. The two-sample *t*-test or Mann--Whitney *U* test was used as appropriate to compare continuous variables between groups. Significance was set at *P*\<0.05. SPSS Statistics, version 24.0 (IBM Corporation, Armonk, NY, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC, USA) were used for data analyses.

Results
=======

Patients and clinical characteristics
-------------------------------------

A total of 67 *C*. *striatum* isolates were identified in different patients. Demographic and baseline characteristics of the 67 patients are summarized in [Table 1](#t1-idr-12-161){ref-type="table"}. Twenty (29.9%) patients had received antibiotics for *C. striatum* isolated from infection sites. Univariate analysis did not indicate significant differences in age, gender, category of infection, and comorbid diseases between the antibiotic treatment and the observation groups ([Table 1](#t1-idr-12-161){ref-type="table"}).

*C. striatum* was isolated from various types of specimens ([Table 2](#t2-idr-12-161){ref-type="table"}). Urine isolates (35.8%) were the most common, but only 10% of these came from those who received antibiotic therapy. Antibiotics were most commonly used in skin abscess isolates (55.0%; [Table 2](#t2-idr-12-161){ref-type="table"}). Of the 67 specimens, 25 (38.8%) were polymicrobial isolates ([Table 2](#t2-idr-12-161){ref-type="table"}). Among these, *Escherichia coli* (16.1%), carbapenem-resistant *Acinetobacter baumannii* (16.1%), and *Pseudomonas* species (16.1%) were the most common simultaneously isolated strains.

Antimicrobial susceptibility
----------------------------

All strains were susceptible to erythromycin, vancomycin, linezolid, and daptomycin ([Table 3](#t3-idr-12-161){ref-type="table"}). However, intermediate to high levels of resistance to penicillin (97.0%), ampicillin (94.0%), cefotaxime (95.5%), and levofloxacin (91.0%) were observed ([Table 2](#t2-idr-12-161){ref-type="table"}). Therefore, the 67 strains may be considered multidrug resistant, defined as resistance to ≥3 classes of antibiotics. There was no significant difference in the frequency of multidrug-resistant isolates between the treatment and observation groups ([Table 2](#t2-idr-12-161){ref-type="table"}).

Based on resistance to penicillin, ampicillin, cefotaxime, levofloxacin, and vancomycin, the 67 *C*. *striatum* strains were classified into five patterns, from I to V ([Table 4](#t4-idr-12-161){ref-type="table"}). Among these, pattern I, which was the multidrug-resistant phenotype susceptible to vancomycin, was the predominant in hospitalized patients (82.8%).

Clinical outcomes
-----------------

Sepsis or septic shock was absent in all cases. Treatment outcomes of the 67 patients are shown in [Table 2](#t2-idr-12-161){ref-type="table"}. Only one (1.5%) patient died during hospitalization. Death was due to a non-infectious cause. Univariate analysis showed no difference between in-hospital mortalities of the treatment and observation groups. The most commonly used therapeutic antibiotics were vancomycin, followed by tigecycline, fluoroquinolones, and piperacillin/tazobactam.

On the other hand, there were no deaths in the 42 patients who had only *C. striatum* isolated from clinical specimens. There was no difference in the length of hospital stay between the treatment and observation groups (9 \[IQR, 0--15\] vs 20 \[IQR, 4--37\] days, *P*=0.049).

MLST
----

Four genes (16S rRNA, ITS1, *gyrA,* and *rpoB*) were analyzed in all strains studied. 16S rRNA was excluded from the reinforcement analysis of MLST due to its high conservation among all strains analyzed. 16S rRNA was used to confirm the identity of *C. striatum* strains. ITS1, *gyrA,* and *rpoB* were used to discriminate among the strains, using a few nucleotide changes within sequences. Distinct allele sequences were assigned arbitrary allele numbers for each locus ([Table S2](#SD2-idr-12-161){ref-type="supplementary-material"}).

In the ITS1 region, allele 2 was the most abundant (52.2%). For *gyrA*, allele 1 was predominant (89.6%). For *rpoB*, allele 2 was the most abundant and was found in 61 strains (91.0%). Twelve sequence types (STs) were identified in these three genes. Of these, the most abundant were ST2 (44.8%), ST3 (22.4%), ST6 (14.9%), and ST5 (4.5%). Among patients with ST2, there were 24 (80.0%) nosoco-mial infections and 6 (20.0%) community-onset infections. Finally, each ST was grouped and schematized ([Figure 2](#f2-idr-12-161){ref-type="fig"}) and analyzed for antibiotic resistance ([Table S2](#SD2-idr-12-161){ref-type="supplementary-material"}). Antibiotic resistance Pattern I occupied an overwhelming number of predominant STs: 28 (93.3%) in ST2, 13 (86.7%) in ST3, and 10 (100%) in ST6.

Discussion
==========

This study analyzed the molecular epidemiology and clinical significance of *C. striatum* isolates recovered from clinical specimens. The data demonstrate the low virulence of *C. striatum,* reflecting its role as a colonizing opportunistic pathogen. However, the characteristics of multidrug resistance and horizontal transmission of *C. striatum* isolates suggest the possibility that it is an emerging nosocomial pathogen, which should be of interest to medical researchers.

*C. striatum* is reportedly susceptible to β-lactams.[@b19-idr-12-161] However, presently, most strains (95.5%) display a multidrug-resistant phenotype, although all strains are susceptible to erythromycin, vancomycin, linezolid, and daptomycin. If *C. striatum* isolates are, indeed, causative agents of infections, they may require the use of broad-spectrum antibiotics such as vancomycin.[@b20-idr-12-161] Antimicrobial resistance is a major global health issue. In ROK, the prevalence of vancomycin-resistant *Enterococcus faecium* has gradually increased from 22% in 2003 to 31% in 2015.[@b21-idr-12-161] Since December 2010, infectious diseases caused by six types of multidrug-resistant bacteria, including vancomycin-resistant enterococci (VRE), were legally designated for surveillance as notifiable infectious microorganisms, with the enactment of the Infectious Disease Control and Prevention Act.[@b22-idr-12-161] To control antimicrobial resistance, contamination and infection by *C. striatum* isolates should be accurately determined to ensure optimal use of antibiotics.

Currently, there are no guidelines for the treatment of infections caused by *C. striatum*. Optimal antimicrobial therapy is still considered controversial. Our in vitro susceptibility tests demonstrate that vancomycin and linezolid are active against *C. striatum*, indicating their potential therapeutic value. However, in the absence of approved breakpoints for *Corynebacterium* species, those antibiotics recommended for *Staphylococcus* species have been used, except for penicillin and ampicillin, for which thresholds for *Listeria* species are used.[@b2-idr-12-161],[@b23-idr-12-161],[@b24-idr-12-161]

In our study, *C. striatum* was isolated from various clinical specimens. However, only 20 (29.9%) patients received antibiotic therapy. For several decades, *C. striatum* has been considered as having limited potential for pathogenicity. The present observations confirmed its low virulence. Similar to *C. striatum* strains, VRE, which exhibit low virulence and pathogenicity, were initially considered rare opportunistic pathogens. However, in recent years, the prevalence of VRE has increased and they have joined the list of significant pathogens that frequently cause nosocomial infections with limited treatment options.[@b25-idr-12-161] Although several factors contribute to virulence, such as host defense mechanisms and the expression of various microorganism traits, a higher rate of multidrug-resistant bacteria may be associated with a higher rate of infection and mortality. Therefore, efforts to contain the spread of multidrug-resistant bacteria should be given prominence by the development of antimicrobial stewardship programs.

Since the first case of *C. striatum* infection in a patient with chronic lymphocytic leukemia was published in 1980, *C. striatum* strains have been considered as emerging pathogens in clinical settings.[@b26-idr-12-161],[@b27-idr-12-161] In recent years, they have been reported as opportunistic pathogens infecting immunocompromised patients with malignancies, COPD, cardiovascular diseases, and diabetes. Other known risk factors include long-term hospitalization, previous use of broad-spectrum antibiotics, and exposure to invasive devices.[@b2-idr-12-161],[@b9-idr-12-161]--[@b11-idr-12-161] In our study, 52 patients (77.6%) presented at least one predisposing condition. This suggests that *C. striatum* may have a significant clinical impact on the patients hospitalized for a long term with comorbidity, or with a history of exposure to broad-spectrum antibiotics, or those who are immunosuppressed, as well as critically ill patients with an implanted indwelling device.

In our study, *C. striatum* strains mainly caused nosocomial infections, and the four predominant STs in MLST, which accounted for 86.6% of the strains, were ST2, ST3, ST6, and ST5. The 67 strains represent distinct allele combinations (13 STs, considering only three genes: ITS1, *gyrA,* and *rpoB*). For *gyrA*, allele 1 was predominant (89.6%). For *rpoB*, allele 2 was the most abundant and was found in 61 strains (91.0%). A literature review indicates that these characteristics of *C. striatum* strains may be a major concern for global health institutions because it is an emergent Gram-positive environmental bacterium which is highly persistent, prevalent, and transmissible person to person and through caregivers, with significant multidrug resistance.[@b2-idr-12-161] Furthermore, it has often caused nosocomial outbreaks.[@b2-idr-12-161],[@b7-idr-12-161]--[@b11-idr-12-161]

Identification of *Corynebacterium* species is challenging because there are limitations to distinguishing *Corynebacterium* species based on biochemical profiles using the Api Coryne system. Thus, as in our study, molecular methods, such as gene sequencing, are used as the complementary gold standard for bacterial identification.[@b28-idr-12-161],[@b29-idr-12-161]

Our study had several limitations. Firstly, this study used a single-center design and included a small sample of specimens. Secondly, antibiotic treatment was decided by the treating physician based on his or her interpretation of the microbiological and clinical parameters used in general clinical practice. Finally, the antibiotic susceptibility test did not include gentamicin, as recommended by the CLSI guidelines. Therefore, the possibility that antibiotic resistance of the strains is more extensive cannot be excluded.

Conclusion
==========

*C. striatum* isolates have been characterized as sources of opportunistic infections associated with nosocomial infections through horizontal transmission. They are only susceptible to a limited number of broad-spectrum antibiotics and can be isolated from clinical specimens due to colonization or contamination. Particularly, characteristics of multidrug resistance and intra-hospital dissemination indicate their potential to be considered as a target pathogen in antimicrobial stewardship programs.

Data sharing statement
======================

Further information and requests for individual deidentified participant data sharing will be fulfilled by contacting the corresponding author YKY (<young7912@korea.ac.kr>) during the 5 years after publication. Clinical and molecular data and research ethics approval information can be shared.

Supplementary materials
=======================

###### 

Primers used in the molecular analysis of 67 *Corynebacterium striatum* strains

  -------------------------------------------------------------------------------------------------------------------------------
  Gene                    Primer     Sequence (5′→3′)         Function                Tª (°C)   Length (bp)   Reference
  ----------------------- ---------- ------------------------ ----------------------- --------- ------------- -------------------
                                                                                                              

  16S rRNA                16SF27\    AGAGTTTGATCMTGGCTCAG\    16S rDNA                55        1,400         [@b26-idr-12-161]
                          16SR1492   TACGGYTACCTTGTTACGACTT                                                   

  16S rRNA (sequencing)   16SF518\   CCAGCAGCCGCGGTAATAC\     16S rDNA                --        --            [@b27-idr-12-161]
                          16SR800    TACCAGGGTATCTAATCC                                                       

  ITS1                    16F945\    GGGCCCGCACAAGCGGTGG\     Interspacer sequence\   55        900           [@b9-idr-12-161]
                          23r458     CTTTCCCTCACGGTAC         region 1                                        

  *gyrA*                  gyrA1\     GCGGCTACGTAAAGTCC\       Gyrase                  55        400           [@b9-idr-12-161]
                          gyrA2      CCGCCGGAGCCGTTCAT                                                        

  *rpoB*                  C2700F\    CGWATGAACATYGGBCAGGT\    β-subunit of RNA\       60        400           [@b9-idr-12-161]
                          C3130R     TCCATYTCRCCRAARCGCTG     polymerase enzyme                               
  -------------------------------------------------------------------------------------------------------------------------------

###### 

STs at three examined loci in the *Corynebacterium striatum* strain and patterns of antimicrobial resistance

  m           16S rRNA   ITS1   gyrA   rpoB   ST[a](#tfn4-idr-12-161){ref-type="table-fn"}   Resistance pattern
  ----------- ---------- ------ ------ ------ ---------------------------------------------- --------------------
                                                                                             
  1           1          2      1      2      2                                              I
  2           1          4      1      2      3                                              I
  3           2          2      1      2      2                                              II
  4           1          2      2      2      4                                              I
  5           1          4      1      2      3                                              I
  6           1          2      1      2      2                                              I
  7           1          4      2      2      5                                              II
  8           3          4      1      2      3                                              I
  9           1          2      1      2      2                                              I
  10          4          3      1      2      6                                              I
  11          5          2      1      2      2                                              I
  12          1          4      1      2      3                                              I
  13          1          4      1      2      3                                              I
  14          1          2      1      2      2                                              I
  15          1          4      1      2      3                                              I
  16          1          3      1      2      6                                              I
  17          1          2      1      2      2                                              I
  18          1          2      1      2      2                                              I
  19          1          2      1      2      2                                              I
  20          6          2      3      3      7                                              II
  21          1          2      1      2      2                                              I
  22          5          2      1      2      2                                              I
  23          1          2      1      2      2                                              I
  24          1          2      1      2      2                                              I
  25          5          2      1      2      2                                              I
  26          1          2      1      2      2                                              I
  27          1          2      1      2      2                                              I
  28          1          3      1      2      6                                              I
  29          1          2      2      2      4                                              I
  30          1          2      1      2      2                                              I
  31          1          2      1      2      2                                              I
  32          1          2      1      2      2                                              I
  33          1          4      1      2      3                                              I
  35          1          4      2      2      5                                              II
  36          1          3      2      2      8                                              I
  39          1          4      1      2      3                                              I
  40          1          4      1      2      3                                              II
  41          5          2      1      2      2                                              I
  42          1          4      1      2      3                                              I
  43          1          2      1      2      2                                              I
  44          1          2      1      2      2                                              I
  45          1          4      1      2      3                                              I
  46          1          2      1      2      2                                              V
  47          1          4      2      2      5                                              III
  48          1          4      1      4      9                                              III
  49          1          2      1      2      2                                              I
  50          1          2      1      2      2                                              I
  51          1          2      1      2      2                                              I
  52          1          2      1      2      2                                              I
  53          1          2      1      2      2                                              I
  54          1          4      1      2      3                                              I
  55          1          2      1      4      10                                             I
  56          1          2      1      2      2                                              I
  57          1          3      1      4      11                                             I
  58          7          3      1      2      6                                              I
  59          1          4      1      5      12                                             I
  61          8          3      1      2      6                                              I
  62          1          3      1      2      6                                              I
  63          1          2      1      2      2                                              I
  64          1          4      1      2      3                                              IV
  65          1          3      1      2      6                                              I
  66          1          3      1      2      6                                              I
  67          1          3      1      2      6                                              I
  69          9          3      1      2      6                                              I
  70          1          4      1      2      3                                              I
  71          1          2      1      6      13                                             I
  72          1          4      1      2      3                                              I
  ATCC 6940   1          1      1      1      1                                              

**Note:**

Only three of the eight loci analyzed were taken into account in obtaining ST numbers (ITS1 region, *gyrA*, and *rpoB* genes).

**Abbreviations:** ITS1, internal transcribed spacer 1; ST, sequence type.
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![Phylogenetic tree based on neighbor-joining method using 16S rRNA gene sequences.\
**Notes:** Distance estimations were calculated using the Kimura two-parameter model. Bootstrap percentages after 1,000 simulations are shown. The *Actinomyces bovis* (T) X81061 sequence was used as an outgroup.](idr-12-161Fig1){#f1-idr-12-161}

![The distribution of STs.\
**Abbreviation:** ST, sequence type.](idr-12-161Fig2){#f2-idr-12-161}

###### 

Demographic and basic characteristics of 67 patients whose clinical specimens tested positive for *Corynebacterium striatum*

  Variables                                                               Total (N=67)      Treatment (n=20, 29.8%)   Observation (n=47, 70.1%)   *P*-value
  ----------------------------------------------------------------------- ----------------- ------------------------- --------------------------- -----------
                                                                                                                                                  
  Male, n (%)                                                             35 (52.2)         14 (70.0)                 21 (44.7)                   0.058
  Age (years), median (IQR)                                               64 (55--78)       65 (59--75)               69 (55--78)                 0.564
  Length from admission to *C. striatum* isolation (days), median (IQR)   15 (3--33)        12 (0--25)                20 (4--37)                  0.615
                                                                                                                                                  
  **Category of infection, n (%**)                                                                                                                0.975
  Community onset                                                         13 (18.8)         4 (20.0)                  9 (19.1)                    
  Hospital acquired                                                       6 (8.7)           2 (1.0)                   4 (8.5)                     
  Nosocomial                                                              48 (71.6)         14 (70.0)                 34 (72.3)                   
                                                                                                                                                  
  **Comorbid illness, n (%**)                                                                                                                     
  Cardiovascular                                                          22 (32.8)         6 (30.0)                  16 (34.0)                   0.785
  Central nervous system                                                  29 (43.3)         5 (25.0)                  24 (51.0)                   0.062
  Malignancy                                                              15 (22.4)         5 (25.0)                  10 (21.3)                   0.756
  Renal                                                                   4 (6.0)           0                         4 (8.5)                     0.309
  Hepatic                                                                 5 (7.5)           2 (10.0)                  3(6.4)                      0.631
  Respiratory                                                             1 (1.5)           0                         1 (2.1)                     1.000
  Hematology                                                              1 (1.5)           0                         1 (2.1)                     1.000
  Transplantation                                                         1 (1.5)           0                         1 (2.1)                     1.000
  Diabetes mellitus                                                       18 (26.9)         7 (35.0)                  11 (23.4)                   0.374
  Charlson's comorbidity index, median (IQR)                              2 (1--3)          2 (0--3)                  2 (1--3)                    0.503
                                                                                                                                                  
  **Risk factors, n (%**)                                                                                                                         
  Recent admission                                                        54 (80.6)         12 (60.0)                 42 (89.4)                   0.392
  Surgery                                                                 24 (35.8)         7 (35.0)                  17 (36.2)                   1.000
  Prior use of antibiotics, n (%)                                         51 (76.1)         14 (70.0)                 37 (78.7)                   0.534
  Steroid                                                                 8 (11.9)          3 (15.0)                  5 (10.6)                    0.687
  Foley catheter                                                          33 (49.3)         8 (40.0)                  25 (53.2)                   0.425
  Mechanical ventilator                                                   27 (40.3)         6 (30.0)                  21 (44.7)                   0.291
  ICU care                                                                23 (34.3)         6 (30.0)                  17 (36.2)                   0.780
                                                                                                                                                  
  **Clinical findings**                                                                                                                           
  Fever, n (%)                                                            2 (3.0)           0                         2 (4.3)                     0.380
  WBC (×10^3^/μL), median (IQR)                                           9.8 (6.1--11.6)   12.1 (6.3--13.2)          8.9 (5.3--11.6)             0.472
  CRP (mg/L), median (IQR)                                                75 (15--130)      109 (31--186)             59 (9--104)                 0.437
  Procalcitonin (ng/mL), median (IQR)                                     2.1 (0.1--2.9)    1.7 (0.1--1.6)            1.7 (0.1--1.6)              0.484

**Abbreviations:** CRP, C-reactive protein; ICU, intensive care unit; WBC, white blood cell.

###### 

Microbiological characteristics and treatment outcomes of 67 patients whose clinical specimens tested positive for *Corynebacterium striatum*

  Parameters                                                                 Total (N=67)   Treatment (n=20, 29.8%)   Observation (n=47, 70.1%)   *P*-value
  -------------------------------------------------------------------------- -------------- ------------------------- --------------------------- -----------
                                                                                                                                                  
  **Category of specimens, n (%**)                                                                                                                0.005
  Urine                                                                      24 (35.8)      2 (10.0)                  22 (46.8)                   
  Skin abscess                                                               22 (32.8)      11 (55.0)                 11 (23.4)                   
  Otitis media                                                               10 (14.9)      2 (10.0)                  8 (17.0)                    
  Blood                                                                      6 (9.0)        1 (5.0)                   5 (10.6)                    
  Ascites                                                                    4 (6.0)        3 (15.0)                  1 (2.1)                     
  Pleural effusion                                                           1 (1.5)        1 (5.0)                   0                           
                                                                                                                                                  
  **Polymicrobial infections, n (%**)                                        25 (38.8)      13 (65.0)                 12 (25.5)                   0.003
  2                                                                          19 (76.0)      9 (69.2)                  10 (83.3)                   
  ≥3                                                                         6 (24)         4 (30.8                   2 (16.7)                    
                                                                                                                                                  
  **Distribution of simultaneously isolated strain, n (%** )                                                                                      
  *Escherichia coli*                                                         5 (16.1)       3 (17.6)                  2 (14.3)                    0.126
  Carbapenem-resistant *Acinetobacter baumannii*                             5 (16.1)       4 (23.5)                  1 (7.1)                     0.011
  *Pseudomonas* species                                                      5 (16.1)       5 (29.4)                  0                           
  Methicillin-resistant *Staphylococcus aureus*                              3 (9.7)        0                         3 (21.4)                    0.248
  *Enterococcus* species                                                     3 (9.7)        0                         3 (21.4)                    0.248
  Methicillin-susceptible *Staphylococcus aureus*                            2 (6.5)        2 (11.8)                  0                           0.028
  Methicillin-resistant coagulase-negative *S. aureus*                       2 (6.5)        0                         2 (14.3)                    0.349
  *Streptococcus* species                                                    2 (6.5)        1 (5.9)                   1 (7.1)                     0.527
  *Enterobacter* species                                                     1 (3.2)        1 (5.9)                   0                           0.122
  *Proteus* species                                                          1 (3.2)        1 (5.9)                   0                           0.122
  *Klebsiella* species                                                       1 (3.2)        0                         1 (7.1)                     0.511
  *Candida* species                                                          1 (3.2)        0                         1 (7.1)                     0.511
                                                                                                                                                  
  **Antibiotic susceptibility, n (%**)                                                                                                            
  Penicillin                                                                 2 (3.0)        0 (0)                     2 (4.3)                     0.525
  Erythromycin                                                               67 (100)       20 (100)                  47(100)                     
  Levofloxacin                                                               6 (9.0)        3 (15.0)                  3 (6.4)                     0.845
  Vancomycin                                                                 67 (100)       20 (100)                  47(100)                     
  Linezolid                                                                  67 (100)       20 (100)                  47(100)                     
  Multidrug resistance, n (%)                                                52 (77.6)      14 (70.0)                 38 (80.9)                   0.106
                                                                                                                                                  
  **Treatment**                                                                                                                                   
  In-hospital mortality, n (%)                                               1 (1.5)        1 (5.0)                   0                           0.290
  Length of hospital stay since *C. striatum* isolation, median days (IQR)   35 (5--77)     31 (1--59)                31 (1--59)                  0.695

###### 

MIC~50~ and MIC~90~ values and antimicrobial susceptibility (%) of the clinical isolates of *Corynebacterium striatum*

  Antibiotics    MIC (mg/L)   Percentage of susceptible isolates                  
  -------------- ------------ ------------------------------------ -------------- -----
                                                                                  
  Penicillin     \>4          \>4                                  0.12--\>4      3.0
  Ampicillin     \>4          \>4                                  0.25--4        6.0
  Cefotaxime     \>2          \>2                                  1--\>2         4.5
  Levofloxacin   \>4          \>4                                  ≤0.5--\>4      9.0
  Erythromycin   \>0.5        \>0.5                                ≤0.06--\>0.5   100
  Linezolid      ≤1           ≤1                                   ≤1             100
  Vancomycin     0.5          1                                    ≤0.25--1       100
  Daptomycin     \<0.25       \<0.25                               \<0.25         100

**Abbreviations:** MIC, minimum inhibitory concentration; MIC~50~, MIC for inhibition of 50% of isolates tested; MIC~90~, MIC for inhibition of 90% of isolates tested.

###### 

Antimicrobial resistance patterns of 67 *Corynebacterium striatum* strains, categorized by susceptibility to penicillin, ampicillin, cefotaxime, levofloxacin, and vancomycin

  Resistance pattern (n)   Patients (n)   Antibiotics                               
  ------------------------ -------------- ------------- ------ ------ ------ ------ ---
  I (58)                   48             10            R(I)   R(I)   R(I)   R(I)   S
  II (5)                   1              4             R(I)   R(I)   R(I)   S      S
  III (2)                  1              1             S      S      S      R(I)   S
  IV (1)                   1              0             R(I)   S      R(I)   R(I)   S
  V (1)                    1              0             R(I)   S      R(I)   S      S

**Abbreviations:** AMP, ampicillin; COF, cefotaxime; I, intermediate; LEV, levofloxacin; PEN, penicillin; R, resistant; S, susceptible; VAN, vancomycin.
